XML 29 R7.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net income (loss) $ 125,664,000 $ (368,445,000) $ (198,382,000)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:      
Depreciation, amortization and accretion 4,158,000 13,276,000 18,575,000
Stock-based compensation expense 5,135,000 8,725,000 48,622,000
Change in fair value of warrant liability (5,369,000)    
(Gain) loss on foreign currency translation (3,433,000) 2,697,000 (10,000)
(Gain) loss on extinguishment of debt (72,024,000) 1,049,000  
Interest incurred through borrowings under Sanofi Loan Facility 4,478,000 1,652,000  
Interest on note payable to principal stockholder 2,901,000 2,894,000 2,894,000
Series A Warrant issuance costs 653,000    
Other, net 19,000    
Loss on sale, abandonment/disposal or impairment of property and equipment 1,259,000 140,582,000 97,000
(Gain) loss on purchase commitments (2,265,000) 66,167,000  
Write-off of inventory   36,104,000  
Write-off of Tranche B commitment asset     1,753,000
Write-off of derivative liability     (363,000)
Changes in operating assets and liabilities:      
Accounts receivable (302,000)    
Receivable from Sanofi (30,534,000)    
Inventory (2,331,000) (26,434,000) (9,670,000)
Receivables from collaboration   50,413,000 (50,436,000)
Deferred costs from commercial product sales (309,000)    
Deferred costs from collaboration 13,539,000 (13,539,000)  
Prepaid expenses and other current assets (346,000) 13,481,000 (14,734,000)
Other assets 361,000 150,000 (615,000)
Accounts payable (12,118,000) 8,413,000 3,622,000
Accrued expenses and other current liabilities 348,000 (12,467,000) 2,276,000
Deferred revenue 3,419,000    
Deferred payments from collaboration (134,056,000) 950,000 200,436,000
Deferred sales from collaboration (17,503,000) 17,067,000  
Recognized loss on purchase commitments 40,566,000    
Milestone rights liability and other liabilities   33,000 21,000
Net cash (used in) provided by operating activities (78,090,000) (57,232,000) 4,086,000
CASH FLOWS FROM INVESTING ACTIVITIES:      
Purchase of property and equipment (1,144,000) (10,285,000) (24,097,000)
Proceeds from sale of property and equipment 17,000 82,000  
Net cash used in investing activities (1,127,000) (10,203,000) (24,097,000)
CASH FLOWS FROM FINANCING ACTIVITIES:      
Proceeds from direct placement of common stock and warrants 50,000,000    
Issuance costs associated with direct placement (2,690,000)    
Payment of notes payable to Deerfield (5,000,000)    
Payment of employment taxes related to vested restricted stock units (165,000) (1,858,000) (26,908,000)
Proceeds from issuance of common stock 893,000 4,146,000 12,341,000
Exercise of warrants for common stock 0 10,123,000 27,779,000
Payment of 2015 notes   (64,287,000)  
Payment of debt issuance costs on 2018 notes   (831,000)  
Proceeds from issuance of facility financing obligation and milestone rights     40,000,000
Proceeds from issuance of Tranche B of the facility financing obligation     20,000,000
Milestone payment   (4,219,000) (3,150,000)
Proceeds from issuance of common stock pursuant to at-the-market issuance   28,392,000  
Issuance costs associated with the Tel Aviv Stock Exchange   (548,000)  
Other   40,000  
Net cash provided by financing activities 43,038,000 5,668,000 70,062,000
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (36,179,000) (61,767,000) 50,051,000
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 59,074,000 120,841,000 70,790,000
CASH AND CASH EQUIVALENTS, END OF PERIOD 22,895,000 59,074,000 120,841,000
SUPPLEMENTAL CASH FLOWS DISCLOSURES:      
Interest paid in cash, net of amounts capitalized to construction in progress 8,991,000 13,355,000 11,218,000
NON-CASH INVESTING AND FINANCING ACTIVITIES:      
Payment of 2015 notes and interest through issuance of common stock   8,253,000  
Issuance of common stock pursuant to debt conversion by Deerfield     93,500,000
Non-cash construction in progress and property and equipment 588,000   1,768,000
Reclassification of deferred payments from collaboration to Sanofi loan facility and loss share obligation 5,174,000 59,337,000 $ 3,034,000
Reclassification of property and equipment to asset held for sale $ 17,294,000    
TEL AVIV STOCK EXCHANGE      
CASH FLOWS FROM FINANCING ACTIVITIES:      
Proceeds from issuance of common stock   36,142,000  
Issuance costs associated with the Tel Aviv Stock Exchange   $ (1,432,000)